STOCK TITAN

AC Immune SA - ACIU STOCK NEWS

Welcome to our dedicated news page for AC Immune SA (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AC Immune SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AC Immune SA's position in the market.

Rhea-AI Summary
AC Immune's clinical data on alpha-synuclein PET tracer ACI-12589 published in Nature Communications shows potential as a diagnostic tool for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
clinical trial
-
Rhea-AI Summary
AC Immune announces upcoming presentations at the 16th CTAD Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
conferences
-
Rhea-AI Summary
AC Immune to present at Jefferies 2023 CNS & Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
conferences
Rhea-AI Summary
AC Immune to present at H.C. Wainwright 25th Annual Global Investment Conference in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
Rhea-AI Summary
AC Immune reports Q2 2023 financial results and provides corporate update. Received FDA Fast Track designation for ACI-24.060 anti-amyloid-beta active immunotherapy. Enrollment in ongoing ABATE study on track. Cash position of CHF 93.0 million finances the Company into Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.72%
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
AC Immune SA

Nasdaq:ACIU

ACIU Rankings

ACIU Stock Data

299.66M
39.64M
41.87%
30.22%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Lausanne

About ACIU

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor